a study on Multiple Myeloma
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). The planned duration of this study is approximately 36 months. Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)
Multiple Myeloma Lenalidomide Thalidomide Antibodies Immunoglobulins Antibodies, Monoclonal Pomalidomide Daratumumab
Open to people ages 18 years and up
Eastern Cooperative Oncology Group (ECOG) performance status score less than or equal to (=) 2
Transaminase levels =2.5 times the upper limit of normal (ULN) (Cohorts A, B, D, E,F)
Total bilirubin =2 times the ULN (Cohorts A, B, D, E, F)
Creatinine =2.0 milligrams per deciliter (mg/dL), with creatinine clearance (CrCl)using the Cockcroft-Gault formula>/=40 milliliters per minute (mL/min) or 60 mL/min for those who receive lenalidomide (Cohorts A, B, D, E, F)
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02431208.
© 2017 The Regents of the University of California